YCYunzhuo Chu

Yunzhuo Chu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yunzhuo Chu has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Fushun Li

    National Clinical Research Center for Medical Auxiliary Technology ( Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China

    5 shared publications
  • Jingjing Chen

    Department of Laboratory Medicine, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, Shenyang, China

    4 shared publications
  • Sufei Tian

    Department of Laboratory Medicine, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, Shenyang, China

    3 shared publications
  • Anhua Wu

    Infection control center, Xiangya Hospital, Central South University, Changsha, 410008, China

    2 shared publications
  • Bijie Hu

    Department of Hospital Infection Management, Zhongshan Hospital, Fudan University, Shanghai 200032, China

    2 shared publications
  • Bin Cao

    Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    A Dual-Phase Strategy to Integrate the VITEK MS RUO Database into Routine Clinical Practice: From Validation of Analytical Performance to Implementation of an Automated Workflow

    by Hua Nian, Fushun Li, Xingqi Wang, Xiaoou Yu, Jinna Dai, Yun-Zhuo Chu

    Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is pivotal in clinical microbiology. The VITEK MS Research Use Only (RUO) database offers broader species coverage, yet its clinical adoption is hindered by insufficient performance validation against the approved in vitro diagnostic (IVD) database and inefficient manual operational workflows. Objective: This two-phase study first aimed to develop and evaluate an automated integrated workflow to enhance laboratory efficiency and diagnostic capability. Methods: The RUO database’s two-tier identification architecture was utilized and in-house automated relay software was developed to parse IVD results and fully automate RUO reanalysis. Phase 1 (Mar 2021–Jun 2022) involved parallel manual testing of 2,432 isolates with both databases to analyze concordance and supplementary performance. Phase 2 (Jul–Nov 2022) prospectively incorporated 3,954 isolates to implement and assess the “IVD screening – automated RUO reanalysis” workflow. Results: Phase 1 demonstrated high RUO-IVD concordance (95.7% species/genus agreement). The RUO database correctly identified 98.9% of isolates and provided valid supplementary identification for 84.4% (108/128) of IVD-failed cases, with Tier 2 contributing 28.9%. Phase 2 revealed that the integrated workflow increased the overall identification rate from 95.5% to 98.7%, with Tier 2 contributing an additional 14.5%. The automated software reduced reanalysis turnaround time by > 75%, saving consumables and labor. Conclusion: The VITEK MS RUO database is a reliable and complementary tool to the IVD database. Integration with automated software creates an efficient, compliant clinical workflow, providing a practical model to enhance pathogen identification for infectious disease management. IMPORTANCE: The present study bridges the validation-to-application gap for the VITEK MS RUO database. We confirm its high concordance (95.7%) and complementary value to the IVD database, quantify the impact of manual workflow inefficiency and introduce an automated software solution. The strategy highlights the key role of Reference Spectra (Tier 2) in expanding coverage and simultaneously improves diagnostic efficacy (∼99% ID rate), operational efficiency (> 75% time saved) and cost-effectiveness, offering a practical model to accelerate pathogen reporting and to guide therapy.

  • Open Access

    Poor glycemic control and smoking and drinking history rather than bacterial virulence contribute to the development of invasive Klebsiella pneumoniae liver abscess: a case–control study in Northeast China

    by Jingjing Chen, Xinyi Wang, Qihui Wang, Sufei Tian, Fushun Li, Ruixuan Wang, Zhihui Chang, Yunzhuo Chu

    Objective: This study aimed to investigate the clinical and microbiological characteristics of invasive and noninvasive Klebsiella pneumoniae liver abscesses (KPLAs) and elucidate the risk factors for invasive KPLA.Methods: We conducted a case–control study involving 50 patients with invasive KPLA and 50 patients with noninvasive KPLA from two medical centers between 2019 and 2024. Demographic and clinical data were collected for all patients from the hospital medical records system. Univariate and multivariate analyses were then performed to compare the characteristics of invasive and noninvasive KPLAs. In addition, antimicrobial resistance testing and whole-genome sequencing were performed for 50 K. pneumoniae strains from one medical center.Results: The comparison of patients with invasive and noninvasive KPLAs revealed that diabetes mellitus, smoking history, drinking history, smaller maximum diameter of abscess, neutrophil count, fasting blood glucose, blood urea nitrogen, and length of hospital stay were independent risk factors for invasive KPLA. Phylogenetic analysis revealed that K. pneumoniae strains from patients with invasive and noninvasive KPLAs were intermingled. ST23 with K1 serotype was the predominant sequence type (66.0%), followed by ST65 with K2 serotype. Multilocus sequence types, capsular serotypes, antimicrobial resistance patterns, virulence genes, and SNPs of K. pneumoniae strains isolated from patients with invasive and noninvasive KPLAs showed no significant differences between the two patient groups.Conclusion: Overall, our results indicate that patients’ contaminant conditions, such as poor glycemic control, smoking history, and drinking history, rather than bacterial virulence, contribute to the development of invasive KPLA.


  • Open Access

    Carbapenem-resistant Enterobacter cloacae complex in a tertiary Hospital in Northeast China, 2010–2019

    by Jingjing Chen, Sufei Tian, Hua Nian, Ruixuan Wang, Fushun Li, Ning Jiang, Yunzhuo Chu

    Background: Carbapenem-resistant Enterobacter cloacae complex (CREC) is a new emerging threat to global public health. The objective of the study was to investigate the clinical characteristics and molecular epidemiology of CREC infections in the medical center of northeast China. Methods: Twenty-nine patients were infected/colonized with CREC during a ten-year period (2010–2019) by WHONET analysis. Antibiotic susceptibilities were tested with VITEK 2 and micro broth dilution method (for polymyxin B and tigecycline). Carbapenemase encoding genes, β-lactamase genes, and seven housekeeping genes for MLST were amplified and sequenced for 18 cryopreserved CREC isolates. Maximum likelihood phylogenetic tree was built with the concentrated sequences to show the relatedness between the 18 isolates. Results: There was a rapid increase in CREC detection rate during the ten-year period, reaching 8.11% in 2018 and 6.48% in 2019. The resistance rate of CREC isolates to imipenem and meropenem were 100.0 and 77.8%, however, they showed high sensitivity to tigecycline, polymyxin B and amikacin. The 30-day crude mortality of CREC infection was 17.4%, indicating that it may be a low-virulence bacterium. Furthermore, molecular epidemiology revealed that ST93 was the predominant sequence type followed by ST171 and ST145, with NDM-1 and NDM-5 as the main carbapenemase-encoding genes. Moreover, E. hormaechei subsp. steigerwaltii and E. hormaechei subsp. oharae were the main species, which showed different resistance patterns. Conclusion: Rising detection rate of CREC was observed in a tertiary hospital, which showed heterogeneity in drug resistance patterns, resistance genes, and MLST types. Effective infection prevention and control measures should be taken to reduce the spread of CREC.


  • Open Access

    Shift in the Dominant Sequence Type of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection from ST11 to ST15 at a Medical Center in Northeast China, 2015–2020

    by Jingjing Chen, Chang Hu, Ruixuan Wang, Fushun Li, Guoquan Sun, Min Yang, Yunzhuo Chu

    Objective: To investigate the clinical characteristics and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection at a medical center in northeast China, especially after coronavirus disease (COVID-19) pandemic. Methods: Fifty-one patients were diagnosed with CRKP bloodstream infection between January 2015 and December 2020, among which 42 isolates were available for further study. Species identification and antibiotic susceptibilities were tested with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and VITEK 2 systems. Carbapenemase genes, virulence genes and MLST genes were detected by polymerase chain reaction. Moreover, the string test and serum killing assay were performed to evaluate the virulence of the CRKP isolates. Results: During the six-year period, the detection rate of CRKP in bloodstream infection showed an increasing trend, with the intensive care unit, hematology and respiratory medicine wards mainly affected. Molecular epidemiology analyses showed that KPC-2 was the dominant carbapenemase gene. In addition, the dominant sequence type (ST) of CRKP shifted from ST11 to ST15 strains, which were all sensitive to amikacin in contrast to the ST11 stains. Furthermore, ST15 CRKP strains were positive for the KfuB virulence gene and more resistant to serum killing compared to the ST11 CRKP strains. Nonetheless, the mortality rate of patients infected with ST11 and ST15 CRKP did not show any significant differences. Conclusion: A shift in the dominant sequence type of CRKP bloodstream infections from ST11 to ST15 was observed during the years 2015– 2020. Compared to ST11, the ST15 CRKP strains showed amikacin sensitivity, positivity for KfuB gene, and serum resistance, which may indicate stronger virulence.


  • Clinical Characteristics and Outcomes of Candidemia Caused by Meyerozyma guilliermondii Complex in Cancer Patients Undergoing Surgery

    by Jingjing Chen, Sufei Tian, Fushun Li, Guoquan Sun, Ke Yun, Shitong Cheng, Yunzhuo Chu

    Although Meyerozyma guilliermondii complex is an uncommon cause of invasive candidiasis worldwide, reported cases, mainly regarding bloodstream infections, increased over years, and patients with cancer who have undergone recent surgery are most commonly affected. However, the clinical characteristics and outcomes of candidemia caused by M. guilliermondii complex remain poorly understood. A retrospective case–control study was conducted to evaluate the clinical characteristics and mortality of candidemia caused by M. guilliermondii complex in cancer patients undergoing surgery. Demographic and clinical data were collected from the hospital medical records system with a standardized data collection form and were analyzed with SPSS 20.0. Sixty-six cancer patients who have undergone recent surgery and were diagnosed with candidemia caused by M. guilliermondii complex were included in the study. Regarding the clinical manifestations, most patients’ body temperatures ranged from 38 to 40 °C, with a median fever duration of 4 (IQR: 3–6) days. Multivariate analysis indicated that the presence of central venous catheter (OR: 6.68; 95% CI 2.80–15.94) and gastric tube (OR: 3.55; 95% CI 1.22–10.34) were independent risk factors for M. guilliermondii complex fungemia. The 30-day crude mortality of candidemia caused by M. guilliermondii complex was 12.1%, twice that of the control group. Moreover, increased WBC count, age ≥ 60 years, septic shock, and ICU admission were identified as predictors of mortality through univariate analysis. These findings will provide a foundation for the clinical management of candidemia caused by M. guilliermondii complex in post-surgical cancer patients.


  • Open Access

    Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant Candida tropicalis and Candida glabrata isolates with delineation of their resistance mechanisms

    by Meng Xiao, Xin Fan, Xin Hou, Sharon Ca Chen, He Wang, Fanrong Kong, Zi-Yong Sun, Yun-Zhuo Chu, Ying-Chun Xu

    Echinocandin antifungal agents have become the first-line therapy for invasive candidiasis (IC) in many countries. Despite their increasing use, resistance to this class of drug is, overall, still uncommon. Here, we report two patients from the People’s Republic of China with IC, one with infection caused by pan-echinocandin-resistant Candida tropicalis and the other by pan-echinocandin-resistant Candida glabrata. We also describe the mechanisms of drug resistance of these isolates. The echinocandin-resistant C. glabrata isolate was cultured from ascitic fluid of a 46-year-old male patient with intra-abdominal IC developing after surgery in 2012. This patient had had no prior antifungal exposure. The echinocandin-resistant C. tropicalis isolate was cultured from chest drainage fluid of a 60-year-old female patient with severe coronary disease and lung infection. Prior to culture and identification of the isolate, the patient had received micafungin treatment for 19 days. Both isolates were cross-resistant to micafungin, anidulafungin, and caspofungin, with minimum inhibitory concentration values of ≥2 µg/mL. The amino acid substitution E655K was found adjacent to the FKS2 HS1 region of the C. glabrata isolate, while the substitution S80P were found in the FKS1 HS1 region of the C. tropicalis isolate. This report highlights the emergence of echinocandin resistance in two important non-albicans Candida species. Although the overall prevalence of echinocandin resistance is low in the People’s Republic of China, monitoring of antifungal susceptibility trends in all Candida species is warranted.


  • Open Access

    Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients

    by Hui Zhang, Qiwen Yang, Kang Liao, Yuxing Ni, Yunsong Yu, Bijie Hu, Ziyong Sun, Wenxiang Huang, Yong Wang, Anhua Wu, et al.

    To evaluate in vitro susceptibilities of aerobic and facultative Gram-negative bacterial (GNB) isolates from intra-abdominal infections (IAIs) to 12 selected antimicrobials in Chinese hospitals from 2012 to 2014. Hospital acquired (HA) and community acquired (CA) IAIs were collected from 21 centers in 16 Chinese cities. Extended spectrum beta-lactamase (ESBL) status and antimicrobial susceptibilities were determined at a central laboratory using CLSI broth microdilution and interpretive standards. From all isolated strains the Enterobacteriaceae (81.1%) Escherichia coli accounted for 45.4% and Klebsiella pneumoniae for 20.1%, followed by Enterobacter cloacae (5.2%), Proteus mirabilis (2.1%), Citrobacter freundii (1.8%), Enterobacter aerogenes (1.8%), Klebsiella oxytoca (1.4%), Morganella morganii (1.2%), Serratia marcescens (0.7%), Citrobacter koseri (0.3%), Proteus vulgaris (0.3%) and others (1.0%). Non- Enterobacteriaceae (18.9%) included Pseudomonas aeruginosa (9.8%), Acinetobacter baumannii (6.7%), Stenotrophomonas maltophilia (0.9%), Aeromonas hydrophila (0.4%) and others (1.1%). ESBL-screen positive Escherichia coli isolates (ESBL+) showed a decreasing trend from 67.5% in 2012 to 58.9% in 2014 of all Escherichia coli isolates and the percentage of ESBL+ Klebsiella pneumoniae isolates also decreased from 2012 through 2014 (40.4% to 26.6%), which was due to reduced percentages of ESBL+ isolates in HA IAIs for both bacteria. The overall susceptibilities of all 5160 IAI isolates were 87.53% to amikacin (AMK), 78.12% to piperacillin-tazobactam (TZP) 81.41% to imipenem (IMP) and 73.12% to ertapenem (ETP). The susceptibility of ESBL-screen positive Escherichia coli strains was 96.77%–98.8% to IPM, 91.26%–93.16% to ETP, 89.48%–92.75% to AMK and 84.86%–89.34% to TZP, while ESBL-screen positive Klebsiella pneumoniae strains were 70.56%–80.15% susceptible to ETP, 80.0%–87.5% to IPM, 83.82%–87.06% to AMK and 63.53%–68.38% to TZP within the three year study. Susceptibilities to all cephalosporins and fluoroquinolones were less than 50% beside 66.5% and 56.07% to cefoxitin (FOX) for ESBL+ Escherichia coli and Klebsiella pneumoniae strains respectively. The total ESBL+ rates decreased in Escherichia coli and Klebsiella pneumoniae IAI isolates due to fewer prevalence in HA infections. IPM, ETP and AMK were the most effective antimicrobials against ESBL+ Escherichia coli and Klebsiella pneumoniae IAI isolates in 2012–2014 and a change of fluoroquinolone regimens for Chinese IAIs is recommended.


  • Open Access

    Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014

    by Qiwen Yang, Hui Zhang, Yao Wang, Zhipeng Xu, Ge Zhang, Xinxin Chen, Yingchun Xu, Bin Cao, Haishen Kong, Yuxing Ni, et al.

    The objective of this study was to investigate the distribution and susceptibility of aerobic and facultative Gram-negative bacilli isolated from Chinese patients with UTIs collected within 48 h (community acquired, CA) or after 48 h (hospital acquired, HA) of hospital admission. From 2010 to 2014, the minimum inhibitory concentrations (MICs) of 12 antibiotics for 4,332 aerobic and facultative Gram-negative bacilli, sampled in 21 hospitals in 16 cities, were determined by the broth microdilution method. Enterobacteriaceae composed 88.5% of the total isolates, with Escherichia coli (E. coli) (63.2%) the most commonly isolated species, followed by Klebsiella pneumoniae (K. pneumoniae) (12.2%). Non-Enterobacteriaceae accounted for only 11.5% of all isolates and included mainly Pseudomonas aeruginosa (P. aeruginosa) (6.9%) and Acinetobacter baumannii (A. baumannii) (3.3%). Among the antimicrobial agents tested, the susceptibility rates of E.coli to the two carbapenems, ertapenem and imipenem as well as amikacin and piperacillin-tazobactam ranged from 92.5 to 98.7%. Against K. pneumonia, the most potent antibiotics were imipenem (92.6% susceptibility), amikacin (89.2% susceptibility) and ertapenem (87.9% susceptibility). Although non-Enterobacteriaceae did not show high susceptibilities to the 12 common antibiotics, amikacin exhibited the highest in vitro activity against P. aeruginosa over the 5-year study period, followed by piperacillin-tazobactam, imipenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin. The Extended Spectrum Beta-Lactamase (ESBL) rates decreased slowly during the 5 years in E. coli from 68.6% in 2010 to 59.1% in 2014, in K. pneumoniae from 59.7 to 49.2%, and in Proteus mirabilis (P. mirabilis) from 40.0 to 26.1%. However, the ESBL rates were different in 5 regions of China (Northeast, North, East, South and Middle-China). E. coli and K. pneumonia were the major pathogens causing UTIs and carbapenems and amikacin retained the highest susceptibility rates over the 5-year study period, indicating that they are good drug choices for empirical therapies, particularly of CA UTIs in China.


  • Open Access

    The inoculum effect of antibiotics against CTX-M-extended-spectrum β-lactamase-producing Escherichia coli

    by Na Wu, Bai Yi Chen, Su Fei Tian, Yun Zhuo Chu

    Questions remain regarding the use of the cephalosporins to treat infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. For example, should ceftazidime or cefepime be used to treat infections with CTX-M ESBL-producing organisms with low MICs (minimum inhibitory concentrations), according to the new Clinical and Laboratory Standards Institute’s (CLSI) recommendations for susceptibility testing? Some studies have reported that in vitro MICs of cephalosporins increase as the inoculum increases, which is the inoculum effect; however, most of the enzymes studied were SHV and TEM. In this study, we aimed to investigate the inoculum effect on ceftazidime, cefepime and four other β–lactam agents against CTX-M-ESBLs-producing Escherichia coli.